A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
Study Details
Study Description
Brief Summary
Lewy body spectrum disorders are a common group of neurodegenerative diseases that cause memory loss, behavioural and motor disabilities that impair quality of life. Cognitive enhancers help people afflicted with these conditions. However, some people do not benefit from this treatment, while others experience serious side effects. Side effects and poor response lead to hospitalization and early institutionalization. Pharmacogenomics, the study of how DNA variation can influence drug effects, will be combined with functional changes in brain imaging in response to cognitive enhancers in patients with Lewy body disease. The goal is to develop a predictive test that can be administered in the clinic to aid physicians' choice of initial medication. This can reduce health care costs and improve treatment to Canadians suffering from these devastating disorders.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Parkinson's Disease Dementia Participants in the Parkinson's Disease Dementia group: Must be taking a stable parkinsonian medication Must have a diagnosis of clinically definite Parkinson's disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents. Response to cholinesterase inhibitor over a period of six months will be monitored. |
Drug: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
|
Dementia with Lewy Bodies Participants in the Dementia with Lewy Bodies group: Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism. Response to cholinesterase inhibitor over a period of six months will be monitored. |
Drug: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
|
Outcome Measures
Primary Outcome Measures
- Change from baseline in perfusion brain SPECT at 6 months [0 and 6 months]
- Change from baseline in neuropsychological assessment scores at 6 months [0 and 6 months]
Secondary Outcome Measures
- Volumetric Brain MRI [Baseline]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Inclusion criteria for patients with a Lewy body spectrum disorder includes: age > 50 years; and mild-moderate dementia (Mini-Mental State Exam [MMSE] > 9); contact on at least four of seven days/week with a responsible caregiver; Hoehn & Yahr stage ≤ 4.
Exclusion Criteria:
- age < 50; Severe dementia (MMSE < 9); contact < 4 days a week with a responsible caregiver; Hoehn & Yahr stage > 4.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sunnybrook Health Sciences Centre | Toronto | Ontario | Canada | M4N3M5 |
Sponsors and Collaborators
- Sunnybrook Health Sciences Centre
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LBD-312-2006